These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18686223)

  • 1. [Basal insulin in discussion--clinical and health economics aspects].
    Middeke M
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S99; discussion S124-6. PubMed ID: 18686223
    [No Abstract]   [Full Text] [Related]  

  • 2. [Are the short-acting insulin analogs superfluous?].
    Arand M
    MMW Fortschr Med; 2006 Mar; 148(11):17. PubMed ID: 16612957
    [No Abstract]   [Full Text] [Related]  

  • 3. [Short acting insulin analogues for type 2 diabetes. Unnecessary additional expenditure or valuable added benefit? Interview by Böhm Sanja].
    Hess R; Kerner W
    Dtsch Med Wochenschr; 2006 Oct; Suppl 1():36-7. PubMed ID: 17595817
    [No Abstract]   [Full Text] [Related]  

  • 4. ["The Lantus case": and yet it does move (or not?)].
    Schöffski O
    Dtsch Med Wochenschr; 2010 Sep; 135(36):1755-6. PubMed ID: 20812163
    [No Abstract]   [Full Text] [Related]  

  • 5. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economics under scrutiny - experts discuss long acting insulin analogs].
    Pflege Z; 2011 Jan; 64(1):58. PubMed ID: 21305792
    [No Abstract]   [Full Text] [Related]  

  • 7. [Costs of antihyperglycemic treatment and consumables and treatment satisfaction in patients with type 2 diabetes].
    Schröder J; Kerner W
    Dtsch Med Wochenschr; 2009 Nov; 134(46):2355; author reply 2355-6. PubMed ID: 19894207
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypoglycaemia, analogue insulins; prescribing cost or quality of life?
    Hitman GA
    Diabet Med; 2012 Mar; 29(3):289. PubMed ID: 22364579
    [No Abstract]   [Full Text] [Related]  

  • 9. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-acting insulin analogues vs. human insulin for diabetes.
    Schooff M; Ehlers K
    Am Fam Physician; 2005 Sep; 72(5):805-7. PubMed ID: 16156336
    [No Abstract]   [Full Text] [Related]  

  • 12. Post-marketing studies of new insulins: sales or science?
    Gale EA
    BMJ; 2012 Jun; 344():e3974. PubMed ID: 22692652
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment: insulin strategies for type 2 diabetes mellitus.
    Davidson JA
    Ann Pharmacother; 2005 May; 39(5):975-6; author reply 976. PubMed ID: 15811902
    [No Abstract]   [Full Text] [Related]  

  • 14. More from PHARMAC on long-acting insulin analogues: insulin glargine now funded.
    Moodie P
    N Z Med J; 2006 Jun; 119(1236):U2040. PubMed ID: 16807582
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current cost analysis in the management of diabetes mellitus].
    Oberender P
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S110-4; discussion S124-6. PubMed ID: 18686219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Insulin analogues--which dimension should be discussed?].
    Verspohl EJ
    Med Monatsschr Pharm; 2006 Jun; 29(6):198-9. PubMed ID: 16792195
    [No Abstract]   [Full Text] [Related]  

  • 18. [Insulin therapy in type 2 diabetes: short-acting insulin analog has advantages].
    MMW Fortschr Med; 2006 Jun; 148(26):56-7. PubMed ID: 16875384
    [No Abstract]   [Full Text] [Related]  

  • 19. [Type 2 diabetes: new insulins and new therapeutic strategies].
    Sauvanet JP
    Diabetes Metab; 2004 Nov; 30(5):478-80. PubMed ID: 15682547
    [No Abstract]   [Full Text] [Related]  

  • 20. [My quality of life has increased with Lantus].
    Euler H
    Lakartidningen; 2004 Sep; 101(39):3015; discussion 3016. PubMed ID: 15493645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.